No Data
No Data
No Data
No Data
No Data
Weigao Co., Ltd. (01066): Weigao Orthopedic (688161.SH)'s net profit of 34.9057 million yuan in the first quarter decreased by 62.92% year-on-year
Weigao Co., Ltd. (01066) announced Weigao Orthopedic (688161.SH) results for the first quarter of 2024, business...
Zhitong FinanceApr 29 18:55
威高股份:2023年報
Futu NewsApr 29 17:32 · Announcements
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
TipRanksApr 9 12:30
DBS: Maintaining the “Buy” Rating of Weigao Shares (01066.HK) and reducing the target price to HK$6.4
DBS released a research report stating that it maintained the “buy” rating of Weigao shares (01066.HK) and lowered the target price from HK$11.6 to HK$6.4.
Zhitong FinanceApr 8 14:26
Weigao Co., Ltd. (1066.HK): Performance under pressure due to collection and base figures
Guide to this report: In 2023, performance is under pressure due to the influence of collection and base figures. As the marginal impact of collection narrows and the base effect declines, it is expected that the normal growth rate will return to normal growth from 2024 and maintain the holding rating. Summary: Maintain an increase in holdings rating. contemplates
國泰君安Apr 7 14:26
Bank Rating | Goldman Sachs: Lowering the target price of Weigao shares to HK$8.7 to maintain a “buy” rating
Glonghui, April 3 | Goldman Sachs released a rating report stating that in the second half of last year, sales of Weigao shares fell 5% year-on-year to 6.3 billion yuan, and net profit fell 35% to 804 million yuan, in line with the earlier profit warning. Management proposed a 5% to 10% year-on-year increase for this year, slightly lower than expected, and raised the dividend ratio from 30% to 40%, considering the company's strong cash flow. The bank said it would adjust the company's earnings estimates per share for each year from 2024 to 26 to a decrease of 2.5%, a decrease of 0.4% and a decrease of 3%, respectively. The target price was lowered from HK$10 to HK$8.7, maintaining its rating as a “buy”.
Gelonghui FinanceApr 3 11:08
No Data
No Data